Division of Plastic Reconstruction Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy.
Eur J Surg Oncol. 2013 Mar;39(3):260-5. doi: 10.1016/j.ejso.2012.12.004. Epub 2013 Jan 10.
A small but significant proportion of patients with breast cancer (BC) will develop loco-regional recurrence (LRR) after immediate breast reconstruction (IBR). The LRR also varies according to breast cancer subtypes and clinicopathological features.
We studied 1742 consecutive BC patients with IBR between 1997 and 2006. According to St Gallen conference consensus 2011, its BC approximations were applied to classify BC into five subtypes: estrogen receptor (ER) and/or progesterone receptor (PgR) positive, HER2 negative, and low Ki67 (<14%) [luminal A]; ER and/or PgR positive, HER2 negative and high Ki67(≥ 14%) [luminal B/HER2 negative]; ER and/or PgR positive, any Ki67 and HER2 positive [luminal B/HER2 positive]; ER negative, PgR negative and HER2 positive [HER2 positive/nonluminal]; and ER negative, PgR negative and HER2 negative [triple negative]. Cumulative incidences of LRR were compared across different subgroups by means of the Gray test. Multivariable Cox regression models were applied.
Median follow up time was 74 months (range 3-165). The cumulative incidence of LRR was 5.5% (121 events). The 5-year cumulative incidence of LRR was 2.5% for luminal A; 5.0% for luminal B/HER2 negative; 9.8% for luminal B/HER2 positive; 3.8% for HER2 non luminal; and 10.9% for triple negative. On multivariable analysis, tumor size (pT) >2 cm, body mass index (BMI) ≥ 25, triple negative and luminal B/HER2 positive subtypes were associated with increased risk of LRR.
Luminal B/HER2 positive, triple negative subtypes and BMI ≥ 25 are independent prognostic factors for risk of LRR after IBR.
一小部分乳腺癌(BC)患者在即刻乳房重建(IBR)后会出现局部区域复发(LRR)。LRR 也根据乳腺癌亚型和临床病理特征而有所不同。
我们研究了 1997 年至 2006 年间 1742 例接受 IBR 的连续 BC 患者。根据圣加仑会议共识 2011 年的标准,将其 BC 近似值应用于将 BC 分为五个亚型:雌激素受体(ER)和/或孕激素受体(PgR)阳性、HER2 阴性和低 Ki67(<14%)[管腔 A];ER 和/或 PgR 阳性、HER2 阴性和高 Ki67(≥ 14%)[管腔 B/HER2 阴性];ER 和/或 PgR 阳性、任何 Ki67 和 HER2 阳性[管腔 B/HER2 阳性];ER 阴性、PgR 阴性和 HER2 阳性[HER2 阳性/非管腔];和 ER 阴性、PgR 阴性和 HER2 阴性[三阴性]。通过灰色检验比较不同亚组之间 LRR 的累积发生率。应用多变量 Cox 回归模型。
中位随访时间为 74 个月(范围 3-165)。LRR 的累积发生率为 5.5%(121 例事件)。5 年 LRR 的累积发生率为管腔 A 为 2.5%;管腔 B/HER2 阴性为 5.0%;管腔 B/HER2 阳性为 9.8%;HER2 非管腔为 3.8%;三阴性为 10.9%。多变量分析显示,肿瘤大小(pT)>2 cm、体质指数(BMI)≥25、三阴性和管腔 B/HER2 阳性亚型与 LRR 风险增加相关。
管腔 B/HER2 阳性、三阴性和 BMI≥25 是 IBR 后 LRR 风险的独立预后因素。